Akut mieloid leukémia (AML): vizsgálatok itt: Franciaország
88 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisFut, nem toborozAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
- Where
- Angers Cedex 9, Caen Cedex 9, Clamart, Clermont-Ferrand, Grenoble Cedex 9, Lille Cedex, Limoges Cedex 1, Marseille, Nice, Orleans Cedex 2, Pessac, Pierre-Bénite, Rennes Cedex 9, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 245 worldwide
- Run by
- Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00 - No phaseTaking peopleStudy of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia
- Where
- Bourgoin, Grenoble, Lyon, Saint-Etienne, Villefranche-sur-Saône
- Életkor
- 18 év and over
- People
- 100
- Run by
- Centre Leon Berard
See details and how to joinNCT07243483 - 3. fázisTaking peoplePhase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
- Where
- Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Créteil, Grenoble, Lille, Limoges, Lyon, Marseille, Montpellier, Nancy, Nantes, Nice, Paris, Poitiers, Rennes, Saint-Etienne, Strasbourg, Toulouse, Tours, Villejuif
- Életkor
- 50 év to 70 év
- People
- 324
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06083129 - 2. fázisTaking peopleCPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
- Where
- Amiens, Angers, Avignon, Besancon Cedex, Béziers, Bobigny Cedex, Caen Cedex 9, Clamart, Clermont Ferrand Cedex 1, Corbeil-Essonnes, Creteil Cedex, Le Chesnay, Lille Cedex, Limoges, Marseille, Marseille Cedex 05, Metz Cedex 03, Mulhouse, Nantes, Nice, Nice Cedex 2, Nimes Cedex 9, Orleans Cedex 2, Paris, Paris Cedex 12, Paris Cedex 13, Pessac, Pierre-Bénite, Roubaix, Rouen, Saint-Etienne Cedex 2, Toulouse Cedex 9, Tours, Villejuif
- Életkor
- 18 év and over
- People
- 248
- Run by
- Centre Hospitalier Universitaire de Nice
See details and how to joinNCT05260528 · EU 2022-500295-60-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Angers, Bobigny, Le Mans, Lille, Limoges, Lyon, Marseille, Nantes, Nice, Paris, Talence, Villejuif
- Életkor
- 12 év and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555 - 1. fázisTaking peopleFirst-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes
- Where
- Marseille, Montpellier Cedex 5, Nice, Paris, Pierre-Bénite
- Életkor
- 18 év and over
- People
- 61
- Run by
- Advanced Biodesign
See details and how to join2024-518813-24-00 - 2. fázisTaking peopleDe-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
- Where
- Marseille, Nantes Cedex 1, Rennes, Talence, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 50
- Run by
- Institut Paoli-Calmettes
See details and how to joinNCT06557421 · EU 2024-514112-28-00 - 2. fázisNot yet taking people in FranciaországStudy Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
- Where
- Angers, Bayonne, Besançon, Clamart, Créteil, Grenoble, Lille, Limoges, Nantes, Nîmes, Paris, Perpignan, Pessac, Pierre-Bénite, Rennes, Rouen, Toulouse, Tours, Vandœuvre-lès-Nancy, Villejuif
- Életkor
- 55 év and over
- People
- 60
- Run by
- French Innovative Leukemia Organisation
See details and how to joinNCT07463768 - No phaseTaking peopleEvaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies
- Where
- Angers
- Életkor
- 18 év and over
- People
- 120
- Run by
- University Hospital, Angers
See details and how to joinNCT07147621 - 1. fázisNot yet taking people in FranciaországStudy With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia
- Where
- Nantes
- Életkor
- 18 év and over
- People
- 12
- Run by
- Nantes University Hospital
See details and how to joinNCT07392814 · EU 2025-524725-41-00 - No phaseTaking peopleQuality of Life-Guided Transfusion in Refractory MDS or AML
- Where
- Nice
- Életkor
- 18 év and over
- People
- 52
- Run by
- Centre Hospitalier Universitaire de Nice
See details and how to joinNCT07328191 - No phaseTaking peopleDetermination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
- Where
- Mulhouse
- Életkor
- 60 év and over
- People
- 30
- Run by
- Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
See details and how to joinNCT07250217 - No phaseNot yet taking people in FranciaországEffect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia
- Where
- Toulouse
- Életkor
- 18 év and over
- People
- 99
- Run by
- University Hospital, Toulouse
See details and how to joinNCT07386392 - 2. fázisTaking peopleStudy Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
- Where
- Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Créteil, Grenoble, Lille, Limoges, Lyon, Marseille, Montpellier, Nancy, Nantes, Paris, Poitiers, Rennes, Saint-Etienne, Toulouse
- Életkor
- 18 év to 99 év
- People
- 302
- Run by
- Nantes University Hospital
See details and how to joinNCT05917405 - 4. fázisTaking peoplePTX3-targeted Antifungal Prophylaxis
- Where
- Créteil Cedex
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Bochud Pierre-Yves
See details and how to joinNCT03828773 · EU 2024-517211-79-00 - No phaseTaking peopleStudy of Families With an Hemopathies Predisposition Related to the DDX41 Gene.
- Where
- Bordeaux, Limoges, Marseille, Montpellier, Toulouse
- Életkor
- 18 év and over
- People
- 910
- Run by
- Institut Claudius Regaud
See details and how to joinNCT06022016 - 1. fázisTaking peopleStudy Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
- Where
- Lille
- Életkor
- 18 év and over
- People
- 5
- Run by
- University Hospital, Lille
See details and how to joinNCT06649227 · EU 2023-509212-29-01 - No phaseTaking peopleOBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
- Where
- Amiens, Angers, Bayonne, Besançon, Clermont-Ferrand, Créteil, Dunkirk, Grenoble, Le Mans, Lyon, Marseille, Meaux, Montpellier, Mulhouse, Nantes, Nice, Orléans, Paris, Pessac, Strasbourg, Toulouse
- Életkor
- 18 év and over
- People
- 250
- Run by
- French Innovative Leukemia Organisation
See details and how to joinNCT06377579 - No phaseTaking peopleStudy of the Medullary Microenvironment in Acute Childhood Leukemia
- Where
- Tours
- Életkor
- 1 év to 15 év
- People
- 40
- Run by
- University Hospital, Tours
See details and how to joinNCT05792007 - No phaseTaking peopleProspective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
- Where
- Amiens, Argenteuil, Bobigny, Caen, Clamart, Corbeil-Essonnes, Créteil, Dijon, Dunkirk, Le Chesnay, Lens, Lille, Limoges, Marseille, Meaux, Nice, Paris, Pierre-Bénite, Pontoise, Roubaix, Rouen, Saint-Cloud, Saint-Quentin, Valenciennes, Villejuif
- Életkor
- 18 év and over
- People
- 5000
- Run by
- Acute Leukemia French Association
See details and how to joinNCT04777916 - 1/2. fázisFelfüggesztveAB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Marseille
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- AB Science
See details and how to joinNCT05211570 · EU 2024-516641-39-00 - 1/2. fázisNot yet taking people in FranciaországAn Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
- Where
- Besançon, Paris
- Életkor
- 18 év and over
- People
- 143 worldwide
- Run by
- Advesya SAS
See details and how to joinNCT06281847 - 3. fázisNot yet taking people in FranciaországIvosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
- Where
- Angers, Bordeaux, Caen, Créteil, Grenoble, Lille, Lyon, Montpellier, Nantes, Nice, Rennes, Rouen, Saint-Etienne, Versailles
- Életkor
- 18 év and over
- People
- 227 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016 - 3. fázisTaking peopleA Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- Where
- Amiens Cedex 1, Bayonne, Bobigny, Le Chesnay Rocquencourt, Mulhouse, Paris, Perpignan Cedex, Toulouse, Vandoeuvre Les Nancy Cedex, Villejuif
- Életkor
- 70 év and over
- People
- 262 worldwide
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07082452 · EU 2025-521634-29-00 - No phaseNot yet taking people in FranciaországStudy of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital
- Where
- Paris
- Életkor
- 18 év and over
- People
- 750
- Run by
- Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT05558943